Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000134-34
    Sponsor's Protocol Code Number:TEAM(B115UCS2019)
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-000134-34
    A.3Full title of the trial
    Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.
    Digiuno intermittente e Metformina nel tumore della mammella invasivo o nel carcinoma duttale in situ. Studio pre-chirurgico randomizzato di fase IIb.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Metformin and Nightly Fasting in Women with Early Breast Cancer
    Metformina e digiuno intermittente nelle donne con tumore al seno
    A.3.2Name or abbreviated title of the trial where available
    TEAM/TRIANGLE TRIAL
    Studio TEAM/TRIANGLE
    A.4.1Sponsor's protocol code numberTEAM(B115UCS2019)
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorENTE OSPEDALIERO OSPEDALI GALLIERA
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMinistero della Salute, Bando RICERCA FINALIZZATA 2019
    B.4.2CountryItaly
    B.4.1Name of organisation providing support- National Institutes of Health (NIH), RFA-CA-19-031 Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Site
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationE.O. Ospedali Galliera
    B.5.2Functional name of contact pointS.C. Oncologia Medica
    B.5.3 Address:
    B.5.3.1Street AddressMura delle Cappuccine 14
    B.5.3.2Town/ cityGenova
    B.5.3.3Post code16128
    B.5.3.4CountryItaly
    B.5.4Telephone number0105634501
    B.5.5Fax number0105634501
    B.5.6E-mailandrea.decensi@galliera.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMetformina a lento rilascio
    D.3.2Product code [nd]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMETFORMINA CLORIDRATO
    D.3.9.1CAS number 1115-70-4
    D.3.9.2Current sponsor code1115-70-4
    D.3.9.3Other descriptive nameMetformin HCl o Glucophage
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number750
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy
    Tumore della mammella con recettori degli estrogeni e/o progesterone positivi non candidate a chemioterapia neoadiuvante
    E.1.1.1Medical condition in easily understood language
    Breast cancer
    Tumore al seno
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level SOC
    E.1.2Classification code 10038604
    E.1.2Term Reproductive system and breast disorders
    E.1.2System Organ Class 10038604 - Reproductive system and breast disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Primary interim objective: assess the safety of the experimental intervention based on the frequency of occurrence of a Dose Limiting Toxicity (DLT) in the first 14 participants assigned to the experimental treatment arm. A DLT is defined as a hypoglycemic event requiring permanent discontinuation of study treatment or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug.
    Primary objective: assess the effect of the combination of prolonged nightly fasting (=16 hours) and Metformin on the change of Ki67 labeling index (LI) in cancer tissue (IBC or DCIS, if IBC is absent) between pre-treatment biopsy and post treatment surgical specimen.
    Co-primary objective: evaluate the difference in post-treatment Ki67 LI in cancer adjacent DCIS (in the presence of IBC), if present, or IEN, defined as atypical ductal hyperplasia or atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS), between the active treatment and the control group.
    Obiettivo primario ad interim: valutare la sicurezza in base alla tossicità limitante definita come un evento ipoglicemico che richiede l'interruzione permanente del trattamento o qualsiasi evento La tossicità limitante è .Obiettivo primario: valutare l'effetto della combinazione di digiuno notturno prolungato (=16 ore) e metformina sulla variazione di Ki67 nel tessuto tumorale (tumore della mammella invasivo o nel carcinoma duttale in situ) tra biopsia pre-trattamento e campione chirurgico post trattamento.
    Obiettivo co-primario: valutare la differenza di Ki67 post-trattamento nel carcinoma duttale in situ (nel caso in cui il carcinoma mammario invasivo sia presente), se presente, o nella neoplasia intraepiteliale adiacenti, definita come iperplasia duttale atipica (ADH) o iperplasia lobulare atipica (ALH) o carcinoma lobulare in situ (LCIS), tra il braccio di trattamento e il braccio di controllo.
    E.2.2Secondary objectives of the trial
    - to explore the effect of intervention on PP2A-GSK3ß-MCL-1 axis in pre-post treatment tissue levels
    - to measure the change on: HOMA index, highly sensitive CRP, C-peptide, IGF-I, IGFBP-1, IGFBP-3, free IGF-I, Hb1Ac, lipid profile, adipokines;
    - to correlate a NGS mutational profile panel focused on ER+ve with the response of Ki67
    - to measure the difference of cell death by IHC for M30 in post- treatment samples between arms;
    - to measure the difference of pS6 by IHC in post- treatment samples between arms;
    - to assess safety and toxicities
    - to measure the change in psychological variables and quality of life between pre and post treatment and the effect modification by distress, anxiety or depression on the intervention effect on Ki67;
    - to correlate eating habits, tobacco/alcohol consumption with the response of Ki67 between arms;
    - to compare the area under the curve of glucose levels between arms and within the experimental arm according to different dose escalation.
    -analizzare l'effetto del trattamento sul cambiamento di PP2A-GSK3ß-MCL-1 nei di tessuti pre e post trattamento
    -misurare la variazione di: HOMA index, PCR ultrasensibile, peptide C, IGF-I, IGFBP-1, IGFBP-3, IGF-I libero, Hb1Ac, profilo lipidico, adipochine
    -correlare un pannello NGS su ER+ con Ki67
    -misurare la differenza di apoptosi cellulare mediante valutazione IHC di M30 in campioni post-trattamento tra i bracci
    -misurare la differenza di pS6 mediante IHC in campioni post-trattamento tra il braccio di trattamento e il braccio di controllo
    -valutare la safety e le tossicità
    -misurare il cambiamento della QOL e delle variabili psicologiche e valutare come influenzino l’efficacia dell'intervento su Ki67 pre e post trattamento
    -correlare le abitudini alimentari, il consumo di tabacco/alcol con la risposta di Ki67 tra il braccio di trattamento e il braccio di controllo
    -confrontare area sotto curva della glicemia tra i bracci e nel braccio sperimentale secondo l'aumento di dose
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Other types of substudies
    Specify title, date and version of each substudy with relative objectives: - Title: TRIANGLE
    - Date:11 Dicember 2021
    - Version: v.3
    - Objectives:
    o test the synergistic effect of the treatment on the change of expression of PP2A-GSK3ß-MCL-1 axis in pre-post treatment tissue levels of BC patients
    o evaluate potential tissue biomarkers and gene/gene expression signature associated with response to treatment to stratify responders from non responders
    o evaluate the change of SUV (standardized uptake value) as a probe of tumor glucose consumption through 18F-FDGPET/CT scan performed pre- and post-treatment

    Altre tipologie di sottostudi
    specificare il titolo, la data e la versione di ogni sottostudio con i relativi obiettivi: - Titolo: TRIANGLE
    - Data: 11 Dicembre 2021
    - Versione: v.3
    - Obiettivo:
    o valutare l’effetto sinergico del trattamento sulla variazione dei livelli di espressione dell’asse PP2A-GSK3ß-MCL-1 nel tessuto di tumore mammario pre- e post-trattamento.
    o valutare potenziali biomarcatori tissutali e la firma genica/dell'espressione genica associata alla risposta al trattamento per stratificare chi risponde e chi no all’intervento.
    o valutare il cambio di SUV (standardized uptake value) come prova del consumo di zucchero da parte del tumore attraverso una valutazione 18F-FDGPET/CT eseguita pre- e post- trattamento.
    E.3Principal inclusion criteria
    - Women with histologically confirmed luminal (ER+ve and/or PgR+ve =1%) operable IBC (cT1-2, cN0-1, Mx) candidate to elective surgery and not to neo-adjuvant treatment. Women with larger tumors who refuse neo-adjuvant chemotherapy before surgery can also be eligible. Luminal HER2+ve IBC and DCIS are also eligible.
    - Age >= 18 years
    - ECOG performance status <=1 (Karnofsky >=70%)
    - Participants must have normal organ and marrow function as defined below:
    o Leukocytes >=3,000/microliter
    o Absolute neutrophil count >=1,500/microliter
    o Platelets >=100,000/microliter
    o AST (SGOT)/ALT (SGPT)<=1.5 × institutional upper limit of normal
    o Creatinine within normal institutional limits
    o Creatinine clearance estimated with Cockcroft-Gault formula: > 45 mL/min
    - Female participants of child-bearing potential must agree to use contraception such as barrier method of birth control or abstinence, prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she has to inform her study physician immediately. The effects of Metformin on the developing human fetus at the recommended therapeutic dose are unknown.
    - Ability to understand and the willingness to sign a written informed consent document.
    -Donne con conferma istologica di tumore della mammella invasivo operabile (cT1-2, cN0-1, Mx) luminale (ER+ e/o PgR+ >=1%) candidate a chirurgia elettiva e non candidate a terapia neoadiuvante. Risultano candidabili anche le donne con tumori di dimensioni maggiori che rifiutano la chemioterapia neoadiuvante prima della chiurgia. Sono candidate al trattamento anche le donne con carcinoma mammario invasivo e carcinoma duttale in situ HER2+.
    - Età >= 18 anni
    - ECOG Performance Status <=1 (Karnofsky >=70%)
    - Normale funzionalità midollare e degli organi come definito di seguito:
    o Leucociti >=3.000 / mL
    o Conta assoluta dei neutrofili >=1,500 / mL
    o Piastrine >=100.000 / mL
    o AST (SGOT) / ALT (SGPT) <=1,5 × limite superiore della norma istituzionale
    o Creatinina entro i normali limiti istituzionali
    o Clearance della creatinina stimata >45 mL / min con formula Cockcroft-Gault
    - Le partecipanti in età fertile devono accettare di utilizzare metodi contraccettivi
    prima dell'ingresso e durante la partecipazione allo studio. Se una donna rimane incinta
    o sospetta di esserlo durante la partecipazione a questo studio, deve informare
    immediatamente il medico. Gli effetti della metformina sullo sviluppo del feto umano
    alla dose raccomandata non sono noti.
    - Capacità di comprendere ed esprimere la volontà di firmare un consenso informato
    E.4Principal exclusion criteria
    - BMI < 18.5 Kg/m2.
    - Previous treatment for breast cancer including chemotherapy and endocrine therapy.
    - Women who are planned to receive neoadjuvant therapy (HER2+ve T2 or N+ve IBC or women < 50 years with luminal B IBC).
    - Triple negative BC.
    - Documented history of symptomatic hypoglycemia.
    - Diabetic patients or participants with fasting glucose level = 126 mg/dL.
    - Known hypersensitivity or intolerance to Metformin.
    - Participants should not be receiving any other investigational agents.
    - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
    - History of lactic acidosis.
    - Liver dysfunction including chronic active hepatitis and cirrhosis not compensated.
    - History of vitamin B12 deficiency or megaloblastic anemia.
    - Chronic use of large doses of diuretics (e.g., >80 mg furosemide)
    - Current use of hormonal contraceptives or female hormones
    - Concomitant use of Topiramate or other carbonic anhydrase inhibitors (e.g., Zonisamide, Acetazolamide or Dichlorphenamide)
    - Pregnant or lactating women.
    - Pregnant women are excluded from this study because even though published data from post-marketing studies have not reported a clear association between Metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when Metformin was used during pregnancy, these studies cannot definitely establish the absence of any Metformin associated risk because of methodological limitations, including small sample size and inconsistent comparator groups. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with Metformin, breastfeeding should be discontinued if the mother is treated with Metformin. Moreover, prolonged fasting is not recommended in pregnant woman.
    -Women who practice any type of intermittent fasting.
    -Women who will not have anyone available to assist them in case of need.
    - BMI <18,5 Kg/m2.
    - Donne precedentemente trattate per il tumore al seno anche con chemioterapia e terapia endocrina.
    - Donne candidate a terapia neoadiuvante (HER2+ T2 o N+ IBC o donne < 50 anni con IBC luminale B).
    - Donne con diagnosi di tumore della mammella triplo negativo.
    - Donne con storia documentata di ipoglicemia sintomatica.
    - Pazienti diabetiche o con glicemia a digiuno >= 126 mg/dL.
    - Nota ipersensibilità o intolleranza alla metformina.
    - Le partecipanti non dovrebbero ricevere altri agenti sperimentali.
    - Patologia in corso non controllata, inclusa, ma non limitata a, infezione in corso o attiva, insufficienza cardiaca congestizia sintomatica, angina pectoris instabile, aritmia cardiaca o malattie psichiatriche / situazioni sociali che limiterebbero la conformità ai requisiti dello studio.

    - Donne con storia di acidosi lattica.

    - Disfunzione epatica inclusa epatite cronica attiva e cirrosi non compensata.

    - Donne con storia di carenza di vitamina B12 o anemia megaloblastica.

    - Uso cronico di grandi dosi di diuretici (ad es.,> 80 mg di furosemide)

    - Uso in corso di contraccettivi ormonali o ormoni femminili

    - Uso concomitante di Topiramato o altri inibitori dell'anidrasi carbonica (ad esempio, Zonisamide, Acetazolamide o Diclorfenamide)

    - Donne in gravidanza o allattamento.

    - Le donne incinte sono escluse da questo studio perché, anche se i dati pubblicati dagli studi post-marketing non hanno riportato una chiara associazione tra metformina e gravi difetti alla nascita, aborto spontaneo o esiti avversi materni o fetali, questi studi sicuramente non possono stabilire l'assenza di qualsiasi rischio associato alla metformina a causa di limitazioni metodologiche, inclusi campioni di piccole dimensioni e gruppi di confronto incoerenti. Poiché esiste un rischio sconosciuto ma potenziale di eventi avversi nei lattanti, secondari al trattamento della madre con metformina, l'allattamento al seno deve essere interrotto se la madre è trattata con metformina. Inoltre, il digiuno prolungato non è raccomandato nelle donne in gravidanza.

    - Pazienti che riferiscono di praticare qualsiasi tipologia di digiuno intermittente.

    - Donne senza assistenza in caso di bisogno.
    E.5 End points
    E.5.1Primary end point(s)
    Primary interim endpoint: The frequency of occurrence of dose limiting toxicity (DLT) in the first 14 participants assigned to the experimental treatment arm will be evaluated as primary interim endpoint. DLT is defined as a hypoglycemic event requiring permanent discontinuation of study treatment or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug.
    Primary endpoint: Change, defined as the difference between post- and pre- treatment levels, of Ki67 LI in IBC or DCIS (in absence of IBC) will be evaluated. For the purpose of the co-primary endpoint the difference in post-treatment Ki67 LI in cancer adjacent DCIS or IEN (defined as ADH or ALH or LCIS) between the active treatment and the control group will be evaluated.
    Endpoint primario ad interim: Sarà valutata la frequenza di insorgenza di tossicità limitanti nei primi 1 partecipantu assegnati al braccio sperimentale. La tossicità limitante è definita come un evento ipoglicemico che richiede l'interruzione permanente del trattamento in studio o qualsiasi evento avverso (EA) di grado 3 o superiore con possibile, probabile o definitiva correlazione al farmaco in studio.
    Endpoint primario: Sarà valutata la variazione, definita come la differenza tra i livelli post e pre-trattamento, di Ki67 nel carcinoma mammario invasivo o nel carcinoma duttale in situ. Per l'endpoint co-primario verrà valutata la differenza nel Ki67 post-trattamento nel carcinoma duttale in situ (nel caso in cui il carcinoma mammario invasivo sia presente) o nella neoplasia intraepiteliale adiacenti, definita come iperplasia duttale atipica (ADH) o iperplasia lobulare atipica (ALH) o carcinoma lobulare in situ (LCIS), tra il braccio di trattamento e il braccio di controllo.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Primary interim endpoint: 4-5 months
    Primary endpoint: 27-28 months
    Endpoint primario ad interim: 4-5 mesi
    Obiettivo primario: 27-28 mesi
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Gruppo di controllo: Monitoraggio in continuo della glicemia
    Control group: Continuous blood glucose monitoring
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months36
    E.8.9.1In the Member State concerned days10
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months36
    E.8.9.2In all countries concerned by the trial days10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 84
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 36
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state80
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 80
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The patient will continue to be followed by the medical staff as before participating in the study.
    il paziente continuerà ad essere seguito dallo staff medico presso cui è in cura come prima della partecipazione allo studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-05-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-05-24
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 20:07:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA